These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22673740)

  • 1. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
    Bareford MD; Hamed HA; Allegood J; Cruickshanks N; Poklepovic A; Park MA; Ogretmen B; Spiegel S; Grant S; Dent P
    Cancer Biol Ther; 2012 Jul; 13(9):793-803. PubMed ID: 22673740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Bareford MD; Park MA; Yacoub A; Hamed HA; Tang Y; Cruickshanks N; Eulitt P; Hubbard N; Tye G; Burow ME; Fisher PB; Moran RG; Nephew KP; Grant S; Dent P
    Cancer Res; 2011 Jul; 71(14):4955-67. PubMed ID: 21622715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Bareford MD; Hamed HA; Tang Y; Cruickshanks N; Burow ME; Fisher PB; Moran RG; Nephew KP; Grant S; Dent P
    Autophagy; 2011 Oct; 7(10):1261-2. PubMed ID: 21814046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
    Park MA; Reinehr R; Häussinger D; Voelkel-Johnson C; Ogretmen B; Yacoub A; Grant S; Dent P
    Mol Cancer Ther; 2010 Aug; 9(8):2220-31. PubMed ID: 20682655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
    Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
    Walker T; Mitchell C; Park MA; Yacoub A; Graf M; Rahmani M; Houghton PJ; Voelkel-Johnson C; Grant S; Dent P
    Mol Pharmacol; 2009 Aug; 76(2):342-55. PubMed ID: 19483104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
    Park MA; Mitchell C; Zhang G; Yacoub A; Allegood J; Häussinger D; Reinehr R; Larner A; Spiegel S; Fisher PB; Voelkel-Johnson C; Ogretmen B; Grant S; Dent P
    Cancer Res; 2010 Aug; 70(15):6313-24. PubMed ID: 20631069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
    Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
    Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.
    Rahmani M; Davis EM; Crabtree TR; Habibi JR; Nguyen TK; Dent P; Grant S
    Mol Cell Biol; 2007 Aug; 27(15):5499-513. PubMed ID: 17548474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I; Pollak Y; Broneshter R; Iancu TC
    FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
    Park MA; Zhang G; Martin AP; Hamed H; Mitchell C; Hylemon PB; Graf M; Rahmani M; Ryan K; Liu X; Spiegel S; Norris J; Fisher PB; Grant S; Dent P
    Cancer Biol Ther; 2008 Oct; 7(10):1648-62. PubMed ID: 18787411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf.
    Matsuzawa Y; Kiuchi Y; Toyomura K; Matsumoto I; Nakamura H; Fujino H; Murayama T; Kawashima T
    J Pharmacol Sci; 2009 Oct; 111(2):182-92. PubMed ID: 19783865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells.
    Tong Y; Huang H; Pan H
    Biochem Biophys Res Commun; 2015 Jan; 456(1):86-91. PubMed ID: 25446102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G; Wang M; Hyslop T; Wang Z; Carr BI
    Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.
    Brüning A; Burger P; Vogel M; Gingelmaier A; Friese K; Burges A
    Invest New Drugs; 2010 Oct; 28(5):535-42. PubMed ID: 19554262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
    Wei G; Wang M; Carr BI
    J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
    Pignochino Y; Grignani G; Cavalloni G; Motta M; Tapparo M; Bruno S; Bottos A; Gammaitoni L; Migliardi G; Camussi G; Alberghini M; Torchio B; Ferrari S; Bussolino F; Fagioli F; Picci P; Aglietta M
    Mol Cancer; 2009 Dec; 8():118. PubMed ID: 20003259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
    Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.